IGC
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
No Graham Number or Intrinsic Value available due to lack of positive earnings.
- P/S ratio of 28.60 is excessive for a non-profitable biotech
- P/B of 3.64 is high given the lack of earnings
Growth metrics are contradictory; short-term Q/Q recovery vs long-term YoY collapse.
- Positive Q/Q revenue growth
- Aggressive analyst price target
- YoY revenue growth is deeply negative (-53.60%)
- Forward P/E remains negative
Long-term historical performance is overwhelmingly negative.
- 5-year price decline of 80.2%
- History of massive earnings misses dating back to 2010
F-Score of 1/9 is a primary indicator of financial fragility.
- Low Debt/Equity ratio
- Piotroski F-Score of 1/9
- Negative ROE (-83.34%) and ROA (-50.31%)
Company is in a growth/survival phase; no dividend capacity.
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IGC and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IGC
IGC Pharma, Inc.
Primary
|
-80.2% | -8.6% | +6.7% | -23.8% | +23.1% | 0.0% |
|
EKSO
Ekso Bionics Holdings, Inc.
Peer
|
-91.1% | -64.0% | +54.0% | +66.6% | -27.2% | -18.0% |
|
NEPH
Nephros, Inc.
Peer
|
-63.0% | +102.8% | +42.6% | -46.5% | -1.4% | +3.6% |
|
CCEL
Cryo-Cell International, Inc.
Peer
|
-52.6% | -3.2% | -34.1% | -15.6% | +23.6% | +6.7% |
|
BTAI
BioXcel Therapeutics, Inc.
Peer
|
-99.8% | -99.6% | -30.1% | -56.4% | -37.0% | -18.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IGC
IGC Pharma, Inc.
|
BEARISH | $31.63M | - | -83.3% | -% | $0.32 | |
|
EKSO
Ekso Bionics Holdings, Inc.
|
BEARISH | $31.11M | - | -107.6% | -91.4% | $8.73 | Compare |
|
NEPH
Nephros, Inc.
|
BEARISH | $30.66M | 26.18 | 12.7% | 6.4% | $2.88 | Compare |
|
CCEL
Cryo-Cell International, Inc.
|
BEARISH | $29.56M | - | -% | -8.5% | $3.67 | Compare |
|
BTAI
BioXcel Therapeutics, Inc.
|
BEARISH | $29.51M | - | -% | -% | $1.09 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | MORAN JAMES P | Director | Stock Award | 130,000 | - |
| 2026-04-01 | MUKUNDA RAM | Chief Executive Officer | Option Exercise | 706,409 | $84,000 |
| 2026-04-01 | PRINS RICHARD K | Director | Stock Award | 170,000 | - |
| 2026-04-01 | GRIMALDI CLAUDIA | Officer and Director | Option Exercise | 238,462 | $36,000 |
| 2026-02-03 | MUKUNDA RAM | Chief Executive Officer | Stock Award | 50,000 | - |
| 2026-01-16 | PRINS RICHARD K | Director | Stock Award | 100,000 | - |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning IGC from our newsroom.